Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problem

Annals of Surgical Oncology

Volumn 9, Issue 8, 2002, Pages 738-744

  Weldon, Christopher B ^a,b   Jaffe, Bernard M ^b   Kahn, Marc J ^b  

^a Tulane Center   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Myelodysplastic syndromes; Secondary leukemias

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MELPHALAN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENICITY; CAUSE OF DEATH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE DISSECTION; MYELODYSPLASTIC SYNDROME; PARTIAL MASTECTOMY; RADIATION HAZARD; TRISOMY 8;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; FATAL OUTCOME; FEMALE; FLUOROURACIL; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, RADIATION-INDUCED; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TAMOXIFEN;

EID: 0036789855     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2001.07.002     Document Type: Article

References (81)

1. Rowley J, Golomb H, Vardiman J. Nonrandom chromosomal abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1977;50: 759-67.
2. Pedersen-Bjergaard J, Larson SO. Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982;307:965-71.
3. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 1992;19:47-84.
4. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000;11(Suppl 1):45-8.
5. Coleman CN, Williams CJ, Flint A, et al. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 1977;297: 1249-52.
6. Coleman CN, Kaplan HJ, Cox R. Leukemia, non-Hodgkin's lymphoma, and solid tumors in patients treated for Hodgkin's disease. Cancer Surv 1982;1:734-44.
7. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am 1993;7:477-93.
8. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cel support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998;124:207-14.
9. Teicher BA. Antitumor alkylating agents. In: DeVita VT, Hellman S. Rosenberg SH, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:405-17.
10. Johnson JM, Ruddon RW. Interaction of nitrogen mustard with polyribonucleotide ribosomes and enzymes involved in protein synthesis in a cell free system. Mol Pharmacol 1967;3:195-203.
11. Strauss BJ. Molecular biology of the response of cells to radiation and to radiomimetic chemicals. Cancer 1977;40:471-80.
12. Boice JD, Greene MH, Killen JY, et al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983;309:1079-84.
13. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-4.
14. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318: 76-81.
15. Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983;43:1891-8.
16. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985;103:195-200.
17. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-7.
18. Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8.
19. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukemia in adults. Br J Cancer 1987;55:523-9.
20. Pedersen-Bjergaard J, Nissen NI, Sorensen HM, et al. Acute nonlymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=dihydroxybusulfan). Cancer 1980:45:19-29.
21. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986;105:360-7.
22. Stott H, Fox W, Girling DJ, et al. Acute leukemia after busulfan. BMJ 1977;2:1513-7.
23. Pedersen-Bjergaard J, Osterlind K, Hansen M, et al. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood 1985;66:1393-7.
24. Fisher B, Rockette H, Fisher ER, et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postop radiation: the NSABP experience. J Clin Oncol 1985;12:1640-58.
25. Andersson M, Philip P, Pedersen-Bjergaard J. High risk therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 1990;65:2460-4.
26. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-51.
27. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol 1997:24:103-13.
28. Auclerc G, Jacquillat C, Auclerc MF, et al. Post-therapeutic acute leukemia. Cancer 1979;44:2017-25.
29. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996;88: 407-18.
30. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
31. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
32. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute myelogenous leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
33. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 1991;78:325-9.
34. Pedersen-Bjergaard J, Phillip P, Larsen SO, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplastic and acute nonlymphocytic leukemias. Blood 1990;76:1083-91.
35. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic factors. J Clin Oncol 1986;4:1748-57.
36. LeBeau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosome numbers 5 and 7. J Clin Oncol 1986;4:325-45.
37. Misra NC, Roberts D. Inhibition by 4′-dmethyl-epipodophyllotoxin 9-(4,6-O-L-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle. Cancer Res 1975;35:99-105.
38. Krishan A, Paika K, Frei E. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 1975;66:521-30.
39. Ross W, Rowe T, Glisson B, et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984;44:5857-60.
40. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974;80:249-59.
41. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993:17:219-52.
42. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993;6:585-97.
43. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA cleavage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
44. Driscoll JS, Hazard GF, Wood HB, Goldin A. Structure-antitumor activity relationships among quinone derivatives. Cancer Chemother Rep 2 1974;4:1-362.
45. Handa K, Sato S. Stimulation of microsomal NADPH oxidation by quinone group-containing anticancer chemicals. Gann 1976;67: 523-8.
46. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-7.
47. Pui CH, Behm FG, Ranimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989;321:136-42.
48. DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangements of chromosome llq. Ann Intern Med 1989; 110:740-2.
49. Yagita M, Ieki Y, Onishi R, et al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Int J Oncol 1998;1:91-6.
50. Smith M, Rubinstein L, Cazenave L, et al. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 1993;85:554-8.
51. Smith M, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77.
52. Domer PH, Head DR, Renganathan N, et al. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4:11). Leukemia 1995;9:1305-12.
53. Hunger SP, Tkachuk DC, Amylon MD, et al. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 1993;81:3197-202.
54. Djabali M, Salleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemia. Nat Genet 1992;2:113-8.
55. Larson RA, LeBeau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome band 11q23 and 21q22 in therapy-related leukemias. Blood 1992;79:1892-3.
56. Pedersen-Bjergaard J, Phillip P. Balanced translocations involving chromosome band 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA topoisomerase II. Blood 1991;78:1147-8.
57. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci 1980;77:1561-5.
58. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988;48:4093-100.
59. Seymour JF, Juneja SK, Campbell LJ, et al. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 1999;13:1735-40.
60. MacGregor JI, Jordan VC. Basic guide to the mechanism of antiestrogen action. Pharmacol Rev 1998;50:151-96.
61. Sutherland RL, Redel RR, Murphy LC, Taylor IW. Effects of antiestrogens on cell cycle progression. In: Jordan VC, ed. Estrogen/Antiestrogen Action and Breast Cancer Therapy. Madison, WI: University of Wisconsin Press, 1986:235-81.
62. Love RR. Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation. Prev Med 1989;18:661-71.
63. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51.
64. Yalcin S, Gullu I, Demiroglu H, Tekuzman G. Acute leukemia during tamoxifen therapy. Med Oncol 1997;14:61-2.
65. Little JB. Cellular, molecular, and carcinogenic effects of radiation. Hematol Oncol Clin North Am 1993;7:337-52.
66. Terasima R, Tolmach LI. X-ray sensitivity abd DNA synthesis in synchronous populations of Hela cells. Science 1963;140:490-2.
67. Sinclair WK, Morton RA. X-ray sensitivity during cell generation cycle of cultured Chinese hamster ovary cells. Radiat Res 1966; 29:450-74.
68. Madoc-Jones H, Mauro F. Age response to x-rays, vinca alkaloids and hydroxyurea of murine lymphoma cells synchronized in vivo. J Natl Cancer Inst 1970;45:1131-43.
69. Hellman S. Cell kinetics, models, and cancer treatment: some principles for the radiation oncologist. Radiology 1975;114:219-23.
70. Hellman S. Principles of cancer management: radiation therapy. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:307- 32.
71. Epstein R, Hanham I, Dale R. Radiotherapy-induced second cancers: are we doing enough to protect young patients? Eur J Cancer 1997;33:526-30.
72. Boice JD, Blettner M, Kleinerman RA, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987;79:1295-311.
73. Boivin JF, Hutchison GB, Evans FB, et al. Leukemia after radio-therapy for first primary cancers of various anatomic sites. Am J Epidemiol 1986;123:993-1003.
74. Curtis RE, Hanley BF, Meyers MH, Young JL. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiological, and End Results Program experience. J Natl Cancer Inst 1984;72:531-44.
75. Curtis RE, Boice JD, Stovall M, et al. Leukemia risk following radiotherapy for breast cancer. J Clin Oncol 1989;7:21-9.
76. Lavey RS, Eby NL, Prosmitz LR. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 1990;66:874-81.
77. Pedersen-Bjergaard J. Radiation- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 1992;16:61-5.
78. Sobeck RM, Beau MML, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:1161-5.
79. Laughlin MJ, McGaughey DS, Crews JR, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplantation. J Clin Oncol 1998;16: 1008-12.
80. Roman-Unfer S, Bitran JD, Hanauer S, et al. Acute myeloid and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant 1995;16:163-8.
81. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995;13: 1557-63.